Research programme: long-acting muscarinic antagonists - Innoviva

Drug Profile

Research programme: long-acting muscarinic antagonists - Innoviva

Alternative Names: LAMA programme - Innoviva

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Class Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Dec 2007 A lead compound from this programme has entered clinical trials
  • 12 Feb 2007 GSK and Theravance are still preclinically developing long-acting muscarinic antagonists
  • 31 Aug 2004 Theravance's LAMA programme has been licensed to GlaxoSmithKline worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top